This is the authors' abstract. We don't add key points for this paper.
Conflict of interest: none declared. Methotrexate is classified as an antimetabolite drug and is used in a number of chronic inflammatory diseases including psoriasis. It is known to inhibit dihydrofolate reductase acting specifically during DNA and RNA synthesis, and therefore has more toxic effects on rapidly dividing cells. The commonest reported side‐effects of methotrexate (> 10%) include nausea, raised liver function results and thrombocytopenia, and, in patients with rheumatoid disease, pulmonary fibrosis. We report two cases of male patients on methotrexate, both with recent onset symptoms of sexual dysfunction. There have been only a few reports of this rare side‐effect in patients treated for rheumatological conditions,1 but to our knowledge, this remains unreported in the dermatology literature. Patient 1 was a 50‐year‐old man with chronic plaque psoriasis, who had been started on weekly oral methotrexate 15 mg for 3 weeks. At clinic review, he reported a 2‐week history of impotence, having had no similar problems before the commencement of methotrexate. This was not associated with any loss of libido. He had no other relevant medical history or medications, and was not known to be diabetic. His treatment was eventually changed to infliximab. Within 4 weeks, there was complete resolution of his impotence.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Wylie et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: